Approvals/HSA/TRIMBOW PRESSURISED INHALATION SOLUTION 200/6/12.5 μg PER ACTUATION

Approved

THERAPEUTIC

TRIMBOW PRESSURISED INHALATION SOLUTION 200/6/12.5 μg PER ACTUATION

Chiesi Farmaceutici SpA (ITALY)🇸🇬 Health Sciences Authority

Approval Date: Apr 30, 2025
Approval ID: e4acc2b5a8e96115
Company: Chiesi Farmaceutici SpA (ITALY)
Type: Therapeutic

Approval Details

Approval Id: e4acc2b5a8e96115
Drug Name: TRIMBOW PRESSURISED INHALATION SOLUTION 200/6/12.5 μg PER ACTUATION
Product Name: TRIMBOW PRESSURISED INHALATION SOLUTION 200/6/12.5 μg PER ACTUATION
Approval Number: SIN17226P
Approval Date: 2025-04-30
Registrant: ORIENT EUROPHARMA PTE LTD
Licence Holder: ORIENT EUROPHARMA PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: AEROSOL, METERED
Dosage: 4.2 Posology and method of administration Posology The recommended dose is two inhalations twice daily. The maximum dose is two inhalations twice daily. Patients should be advised to take Trimbow every day even when asymptomatic. If symptoms arise in the period between doses, an inhaled, shortacting beta2-agonist should be used for immediate relief. When choosing the starting dose strength of Trimbow (100/6/12.5 micrograms or 200/6/12.5 micrograms), the patients’ disease severity, their previous asthma therapy including the inhaled corticosteroid (ICS) dose as well as the patients’ current control of asthma symptoms and risk of future exacerbation should be considered. Stepping-down treatment Patients should be regularly reassessed by a doctor, so that their doses of beclometasone/formoterol/glycopyrronium remain optimal and are only changed on medical advice. The doses should be titrated to the lowest doses at which effective control of asthma symptoms is maintained. There are no data on the effect of stepping-down from the high strength (Trimbow 200/6/12.5 micrograms) to the medium strength beclometasone dipropionate medicinal product (Trimbow 100/6/12.5 micrograms). Special populations Elderly No dose adjustment is required in elderly patients (65 years of age and older). Renal impairment Trimbow can be used at the recommended dose in patients with mild (glomerular filtration rate [GFR] ≥50 to <80 mL/min/1.73 m2) to moderate (GFR ≥30 to <50 mL/min/1.73 m2) renal impairment. Use in patients with severe (GFR <30 mL/min/1.73 m2) renal impairment or end-stage renal (GFR <15 mL/min/1.73 m2) disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic impairment There are no relevant data on the use of Trimbow in patients with severe hepatic impairment (classified as having Child-Pugh class C) and the medicinal product should be used with caution in these patients (see sections 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population The safety and efficacy of Trimbow in the paediatric population (under 18 years of age) have not yet been established. No data are available. Method of administration For inhalation use. To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler correctly by a physician or other healthcare professional, who should also regularly check the adequacy of the patient’s inhalation technique (see “Instructions for use” below). The patient should be advised to read the Package Insert carefully and follow the instructions for use as given in the insert. This medicinal product is provided with a dose counter on the back of the inhaler, which shows how many actuations are left. Each time the patient presses the container a puff of the solution is released and the counter counts down by one. The patient should be advised not to drop the inhaler as this may cause the counter to count down. Instructions for use Priming the inhaler Before using the inhaler for the first time, the patient should release one actuation into the air in order to ensure that the inhaler is working properly (priming). Before priming the 120 actuation pressurised containers, the counter should read 121. After priming, the counter should read 120. Use of the inhaler The patient should stand or sit in an upright position when inhaling from their inhaler. The steps below should be followed. IMPORTANT: steps 2 to 5 should not be performed too quickly: <ol> <li>The patient should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.</li> <li>The patient should breathe out slowly and as deeply as comfortable, in order to empty their lungs.</li> <li>The patient should hold the inhaler vertically with its body upwards and place the mouthpiece between the teeth without biting. The lips should then be placed around the mouthpiece, with the tongue flat under it.</li> <li>At the same time, the patient should breathe in slowly and deeply through the mouth until the lungs are full of air (this should take approximately 4 – 5 seconds). Immediately after starting to breathe in, the patient should firmly press down on the top of the pressurised container to release one puff.</li> <li>The patient should then hold the breath for as long as comfortably possible, then remove the inhaler from the mouth and breathe out slowly. The patients should not breathe out into the inhaler.</li> <li>The patient should then check the dose counter to ensure it has moved accordingly.</li> </ol> To inhale the second puff, the patient should keep the inhaler in a vertical position for approximately 30 seconds and repeat steps 2 to 6. If mist appears after the inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeated from step 2. After use, the patient should close the inhaler with the protective mouthpiece cap and check the dose counter. After inhaling, the patient should rinse the mouth or gargle with water without swallowing it or brush the teeth (see also section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). When to get a new inhaler The patient should be advised to get a new inhaler when the dose counter shows the number 20. He/she should stop using the inhaler when the counter shows 0 as any puffs left in the device may not be enough to release a full actuation. Additional instructions for specific groups of patients For patients with weak hands it may be easier to hold the inhaler with both hands. Therefore, the index fingers should be placed on the top of the pressurised container and both thumbs on the base of the inhaler. Patients who find it difficult to synchronise aerosol actuation with inspiration of breath may use the AeroChamber Plus spacer device, properly cleaned as described in the relevant leaflet. They should be advised by their doctor or pharmacist about the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled active substance to the lungs. This may be obtained by the patients using the AeroChamber Plus by one continuous slow and deep breath through the spacer, without any delay between actuation and inhalation. Alternatively, patients may simply breathe in and out (through the mouth) after the actuation, as instructed in the spacer leaflet, to obtain the medicinal product (see sections 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Cleaning For the regular cleaning of the inhaler, patients should remove weekly the cap from the mouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth. They should not remove the pressurised container from the actuator and should not use water or other liquids to clean the mouthpiece.
Route Of Administration: RESPIRATORY (INHALATION)
Indication Info: 4.1 Therapeutic indications Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Atc Code: R03AL09
Pharma Manufacturer Name: ORIENT EUROPHARMA PTE LTD

Active Ingredients

Beclometasone dipropionate

0.20000mg/actuation

Formoterol fumarate dihydrate

0.00600mg/actuation

Glycopyrronium bromide

0.01250mg/actuation

Beclometasone dipropionate

0.20000mg/actuation

Formoterol fumarate dihydrate

0.00600mg/actuation

Glycopyrronium bromide

0.01250mg/actuation

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Apr 30, 2025

Approval ID

e4acc2b5a8e96115

Type

Therapeutic

Back to HSA Approvals